Defined HMO isomers • Fucosylated and sialylated targets • Research panels

Human Milk Oligosaccharide Synthesis Services

BOC Sciences supports human milk oligosaccharide synthesis for microbial-interaction, pathogen-adhesion, receptor-recognition, and analytical research. Targets include 2'-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, 3'-sialyllactose, 6'-sialyllactose, and specified extended HMOs. Linkage identity, reducing-end state, final derivative, and the evidence needed to distinguish related isomers are established for each material.

  • 2'-FL, 3-FL, LNT, LNnT, 3'-SL, and 6'-SL specified individually
  • Isomer comparisons with matched final formats
  • Research derivatives and target-specific analytical records

Discuss Your Target Explore Synthesis Options

Text-only paired cards distinguish 2-prime-FL and 3-FL, LNT and LNnT, and 3-prime-SL and 6-prime-SL.The requested HMO comparison pairs. Fucose position, terminal galactose linkage, and sialic-acid linkage distinguish each pair; exact sequences are provided in the table.

Project specification

Define the target and intended use
01 HMO name and complete sequence
02 Fucose or sialic-acid linkage
03 Core, branches, and extensions
04 Free reducing end or derivative
05 Isomer controls and analytical needs
06 Amount, final form, and intended assay

Custom synthesis scope

HMO Synthesis by Core Sequence and Terminal Modification

Closely related HMOs can share a composition while differing in a biologically important linkage or attachment position. A project specification pairs the familiar abbreviation with an explicit sequence and final material form.

01
Fucosylated lactose

Fucosyllactose Targets: 2'-FL and 3-FL

Discuss 2'-FL with Fuc alpha1,2 linked to the galactose of lactose, or 3-FL with Fuc alpha1,3 linked to the glucose residue. These are different positional structures despite sharing monosaccharide composition. A comparison panel identifies each material separately and aligns purity, reducing-end state, and any derivatization.

  • Fucose position and linkage defined
  • Separate identities for both isomers
  • Matched final state for comparisons
02
Neutral tetraoses

Neutral Core Structures: LNT and LNnT

Plan LNT with terminal Gal beta1,3 linked to GlcNAc, or LNnT with terminal Gal beta1,4 linked to GlcNAc. Both retain the lactose-based reducing-end sequence specified below. The type-1/type-2 terminal distinction is not resolved by intact mass alone and remains part of the structural evidence requirement.

  • Type-1 or type-2 terminal unit
  • Complete tetrasaccharide sequence
  • Linkage-sensitive identity evidence
03
Sialylated lactose

Sialyllactose Targets: 3'-SL and 6'-SL

Prepare specified Neu5Ac-containing sialyllactose with alpha2,3 or alpha2,6 linkage to the galactose of lactose. The sialic-acid identity, salt form where relevant, and final handling requirements are recorded. Synthesis and isolation must preserve the desired sialylated product and distinguish residual lactose or other related species.

  • Neu5Ac identity and linkage
  • Counterion and delivered form
  • Sensitive-product handling review
04
Additional HMO targets

Extended HMO Panels and Defined Derivatives

Assess larger lactose-based structures, branching, combined fucosylation or sialylation, and specified labels or attachment groups. Expanded targets require a complete drawing rather than a broad request for complex HMOs. A derivative is identified separately from the corresponding free HMO because its reducing end or presentation may influence use.

  • Branch and terminal modification map
  • Free HMO versus labeled derivative
  • Target-specific route feasibility
HMO planning defines the core and linkages, assesses chemical or enzyme-mediated assembly, separates relevant precursors and isomers, and confirms the isolated material.

Target-specific route assessment

Select Linkage-Specific Assembly and Plan Isomer Separation

Chemical, enzymatic, and chemoenzymatic routes offer different ways to reach HMO structures. The practical choice depends on linkage selectivity, precursor availability, enzyme substrate scope, final format, and the scale required for the particular study.

Choose the Core and Extension Sequence

The route begins with the correct lactose-based acceptor or a suitable protected precursor. LNT and LNnT require different terminal galactose connections. Larger structures also require branch and extension order to be defined before selecting the assembly sequence.

Match Enzymes to the Exact Linkage

Fucosyltransferases and sialyltransferases provide linkage-specific options when the intended acceptor is accepted. Activity depends on the actual substrate, derivatization, and reaction conditions. Literature demonstrations support route assessment without establishing that every extended or labeled analog will be converted efficiently.

Remove Precursors and Preserve Final Identity

Purification is planned for the HMO and its likely residual lactose, partial-extension products, salts, nucleotide-related materials, or isomers. Sensitive sialylated structures and final labels may require different processing conditions. The analytical record describes the isolated final product rather than only reaction conversion.

Discuss the Synthesis Route

Material and project decisions

Linkage Definitions for the Six Requested HMO Targets

Sequences are written from the nonreducing side toward reducing-end glucose. Parentheses identify the fucose branch in 3-FL. A free reducing end can mutarotate; that behavior is distinct from an unintended linkage isomer.

HMOLinkage-defined sequenceDistinguishing feature
2'-FLFuc alpha1-2 Gal beta1-4 GlcFucose is attached to galactose O2
3-FLGal beta1-4 (Fuc alpha1-3) GlcFucose is attached to glucose O3
LNTGal beta1-3 GlcNAc beta1-3 Gal beta1-4 GlcTerminal type-1 Gal beta1-3 GlcNAc unit
LNnTGal beta1-4 GlcNAc beta1-3 Gal beta1-4 GlcTerminal type-2 Gal beta1-4 GlcNAc unit
3'-SLNeu5Ac alpha2-3 Gal beta1-4 GlcSialic acid is attached to galactose O3
6'-SLNeu5Ac alpha2-6 Gal beta1-4 GlcSialic acid is attached to galactose O6

Our broader Glycan Synthesis Services support related defined oligosaccharide projects. For attached HMO formats, discuss the reducing-end chemistry and intended display through Glycan Conjugation Services.

Structure-to-data consistency

Distinguish HMO Isomers and Document the Delivered Material

A mass match does not distinguish 2'-FL from 3-FL, LNT from LNnT, or 3'-SL from 6'-SL. The characterization plan combines structural identity, separation, and final-form information appropriate to each target.

Explore Glycan Separation

Composition

Expected Mass and Final Derivative

Appropriate mass analysis supports the residue composition and any label or attachment group. Isomeric HMOs can share the same mass, so composition evidence is interpreted alongside linkage-sensitive data. Salt forms and relevant adducts are considered for sialylated targets.

Linkages

Isomer-Sensitive Structural Evidence

Suitable NMR, fragmentation, enzymatic, or reference-based evidence is selected for the structure. The package identifies how the fucose position, terminal Gal linkage, or sialic-acid linkage is supported. A retention time without a suitable reference and method context is not a universal structural assignment.

Purity

Residual Lactose and Related Oligosaccharides

Chromatographic methods are selected to detect relevant precursor and product species. Reported area purity is tied to the detector and separation achieved. Quantitative assay, water, salt, or residual measurements are additional specifications where the study requires them; area purity is not interchangeable with dry-mass content.

Use format

Reducing End and Handling Requirements

Free HMOs and reducing-end derivatives are documented as distinct materials. A label can change recognition or microbial utilization, so final format is chosen with the assay. Research synthesis does not establish food-grade status, infant-nutrition suitability, or nutritional efficacy.

Research applications

Defined HMOs for Interaction and Analytical Research

HMO panels can isolate linkage and terminal-modification effects in controlled experiments. Outcomes depend on the microbial strain, binding partner, assay conditions, and molecular presentation.

Microbial Utilization and Interaction Studies

Compare individual HMOs as specified substrates or interaction probes in defined microbial systems. Residual lactose or other utilizable sugars can confound interpretation, so relevant impurities and concentration basis should be included in the specification. Utilization by one strain does not establish a universal microbiome effect.

Pathogen Adhesion Research

Investigate whether a defined HMO alters binding in a selected adhesion model. Include appropriate HMO isomers and assay controls. An in vitro adhesion result does not establish prevention of infection or a clinical benefit.

Receptor and Lectin Recognition

Use linkage-defined pairs to investigate fucose- or sialic-acid-dependent recognition. Match reducing-end state, linker, and display across derivatives where possible. Binding behavior in a multivalent format may differ from the free HMO.

HMO Separation and Identification Methods

Discuss structurally assigned materials for method development, retention comparisons, and isomer discrimination. A research reference is not automatically a certified reference material. Quantitative use requires an appropriate content value, uncertainty, and qualification scope.

A defined synthesis project

Develop an HMO Request into a Linkage-Defined Material Panel

The project aligns familiar HMO names with exact structures, expected interfering species, and the requirements of the intended study.

Project brief

Send the structure and project requirements

Provide the HMO names and sequences, free or derivatized reducing end, comparison isomers, amounts, assay type, and required identity, content, or residual tests.

Start an Inquiry

1 Confirm the HMO Structures

Resolve abbreviations, terminal linkages, branches, and sialic-acid identity. Define the delivered reducing-end form.

2 Select Isomer and Assay Controls

Choose the comparison pairs and any lactose or related-oligosaccharide controls needed to interpret the experiment.

3 Assess Assembly and Purification

Review chemical or enzymatic routes, substrate acceptance, product sensitivity, and removal of relevant precursors or related species.

4 Prepare and Characterize Each HMO

Isolate the materials and collect composition, linkage-sensitive identity, and separation data. Add content or residual tests when specified.

5 Deliver the Defined Panel and Records

Provide member-specific analytical documentation and handling information. Identify research references and optional functional studies according to their agreed scope.

Project advantages

Advantages of a Linkage-Defined HMO Synthesis Project

BOC Sciences scopes HMO materials around the exact isomer and analytical resolution required for the research comparison.

Unambiguous Isomer Selection

Common HMO abbreviations are paired with complete sequences and final material forms.

Assay-Relevant Impurity Planning

Residual lactose, partial extension, and related structures are considered in purification and analytical specifications.

Comparable HMO Panels

Free or functionalized formats can be coordinated across the selected members, with biological interpretation kept tied to the tested system.

One connected glycan platform

Connect Human Milk Oligosaccharide Synthesis with Related Services

Related insights

Resources for Human Milk Oligosaccharide Synthesis

Explore supporting information on synthesis, characterization, and material selection for your project.

Structural Isomerism in Glycans: Analytical Challenges and Resolution StrategiesAnalytical Techniques for Glycan CharacterizationLiquid Chromatography Strategies for Glycan Separation: HILIC, RP, and PGC

Frequently asked questions

Human Milk Oligosaccharide Synthesis FAQ

Answers to common questions about the requested structures, characterization, and project scope.

Can the six listed HMOs be assessed in one project?

Yes. List 2'-FL, 3-FL, LNT, LNnT, 3'-SL, and 6'-SL individually with amounts, final formats, and analytical requirements. Each is a separate target even where a pair shares its composition.

References

  1. Xiao Z et al. Chemoenzymatic Synthesis of a Library of Human Milk Oligosaccharides. The Journal of organic chemistry, 2016, 81(14):5851-5865. DOI: 10.1021/acs.joc.6b00478.
  2. Li T et al. An automated platform for the enzyme-mediated assembly of complex oligosaccharides. Nature chemistry, 2019, 11(3):229-236. DOI: 10.1038/s41557-019-0219-8.
  3. Wu Y et al. Automated chemoenzymatic modular synthesis of human milk oligosaccharides on a digital microfluidic platform. RSC advances, 2024, 14(25):17397-17405. DOI: 10.1039/d4ra01395f.

Define the research material your project needs

Discuss Human Milk Oligosaccharide Synthesis with BOC Sciences

Send your HMO list and exact sequences to BOC Sciences, including comparison isomers, final reducing-end format, amounts, and intended study. Identify any content, residual-lactose, or additional analytical requirements. We can assess a route and documentation package for the defined HMO materials your interaction or analytical research needs.

Contact BOC Sciences to discuss target-specific feasibility, specifications, and the required analytical package. Materials are intended for research use.

Request a Custom Quote
* Only for research. Not suitable for any diagnostic or therapeutic use.
Send Inquiry
Verification code